Member Info for maccking

Sorry for two posts below. The first one didn't appear so repeated it!!

Possibly due to the sale of 500000 at the end of last week. These probably were the 500000 shares from the exercise of options by an ex-director earlier in the week.
Any buying or selling, even in such small quantities as today, produces large movements due to lack of available free stock. All is looking very positive for Redx, with a good flow of news on the progress of the research. Redx has a number of lines of research all showing great prospects. They also have a lot of interest and support from major large pharmas. They are also assembling a highly qualified team of top scientists in their fields.
There is always the possibility of a Nasdaq quote. ( purely my supposition due to Redx recently appointing a Finance Director domicile in The USA.)
Medium to longer-term Redx could develop into a major player in medical research. So far it is very much under the radar of investors.

Possibly the sale to safe hands of the 500,000 exercised options at the end of last week. Must be no stock about now that the short-termers sold out in the retracement to 75p following the rapid rise to 129. Taken very few buys this am to get a rise of 10%. Redex seems to be on the cusp of some really exciting and transformational news over the next 12 months and that news could come at any time.

Redx has a webinar hosted by Proactive at 6.00 pm on the 21st of October. You can register on the Proactive website. Should be worth listening to for up-to-date information on progress.

The SP suggests another issue of options is on the cards. Price-performance over the last 2/3 weeks has been very hard to comprehend. The lack of free shares makes for volatility in certain circumstances but retracing all the gains seems very strange. All news has been positive and there is a presentation next week which one would expect to have some more optimism on the progress on the various strands of research. With the benefit of hindsight, I should have sold out at 120ish and repurchased today!! However when in for the long term it hardly matters...but it is very annoying at the same time!

Happy to read a contrarian view.

Happy

Hardly seems likely that bad news will be announced at such a high-profile presentation. The SP seems to be moving up in anticipation of said update which is a good sign. As far as I am concerned any short-term movement, either way is irrelevant. Redx is one for the longer term to extract real value from their research.

This might be of interest to contributors to this page.
There is a Redx virtual R&D day on 11th October between 13.00 and 14.30 BST
Updates on RXC004 with a summary of results presented at ESMO with commentary from leading experts.
Potential of porcupine inhibition RXc004 in colorectal, pancreatic, and biliary cancers.
Updates on company pipeline beyond RXC004
Q and A sessions with leading experts and company leadership.
email :-
redxpharma@fticonsulting.com
to register attendance

This is the link to the full content.
https://www.trinitydelta.org/research-notes/rezurock-approval-has-positive-read-across-for-redx/

This little extract may be of interest. It is from Trinity Delta and was published a couple of weeks ago:
Redx Pharma has established a notable reputation for its medicinal chemistry expertise which it is exploiting through a combination of in-house developed programmes and partnerships (with AstraZeneca and Jazz Pharmaceuticals). The lead programme is RXC004, a porcupine inhibitor poised to enter Phase II studies in a selection of genetically selected solid tumours. RXC007 is the second in-house compound and Rezurock’s approval creates a clear regulatory pathway and, in our view, materially de-risks RXC007’s development process. Our rNPV model, employing conservative assumptions, generates a £350.7m valuation, equivalent to 128p/share (86p fully diluted).

https://en.calameo.com/read/0061133858ca2dc71f390?page=14
This is a link to an article taken from the July/August edition of Pharmafocus. In it
Jane Robertson the CMO of Redx gives some interesting insight into the progress being made with the various oncology drug candidates on offer.

Just had a notice that Redx is having a virtual R&D day on the 11th of October. It is due to start at 13.00 ending around 14.30. They must expect to be able to announce some significant updates on the progress of the various projects being undertaken.

email to redxpharma@fticonsulting.com for an invitation.
For clarity, I am just an ordinary shareholder and have no other connection with the company or FTI.

I have a feeling that the share price is probably being kept at this level for a reason. One thing for sure is that Redx is a company that is very much under the radar. I hope it stays that way and things are allowed to develop without the daytraders getting involved. The outlook for the future is extremely exciting even if it takes a few years to materialise fully. Certainly very positive news today.

It appears that the holder of yesterday's exercised options has sold their entitlement. I wonder who the buyer is. We should get an RNS early next week.

The SP will move to a new level in its own time. So few free shares on the market that the company and large shareholders are in charge. If Pi's suddenly start attempting to buy in any quantity then maybe there will be some excitement. I would much prefer a slow and steady rise based on hard acts rather than out-and-out speculation. A lot is going on behind the scenes and news can come at any time. One question which I don't have an answer to is why go to America for a CFO. Could be just simply that the job can be done from anywhere with modern tech. However, being close to base would usually be the norm. Perhaps Redmile has insisted, or maybe the Redx board is looking at developments in the US.

Half year results on 7 June. Analyst update at 12.00 noon same day.

This is a link to a 5 min presentation which is very positive. Lisa Anson explains the latest on the clinical trial assessing RXC004 alongside anti-PD-1 Click the link here to watch the interview:
https://bit.ly/2PViMg6

Out of interest to members might be this reply received from our Chairman when I last contacted CRV asking for contact details for CRH. It is of little help, the only possibility it alludes to is that some up-to-date accounts for CRH are well overdue! There is also an email address provided for CRH.
Cheers

Sir

All company information regarding Craven Industrial Holdings will be distributed to shareholders of record in accordance with the articles of association. The annual results for CIH for the year to May 2020 nor any other shareholder communication have been published.

The letter sent out to holders of shares in Craven Industrial Holdings at the time of mailing out share certificates made the process in place for the sale/purchase of shares clear. I will repeat this for you here;

"In the event that you wish to sell any shares in CIH or acquire further shares please email info@cihplc.com stating the number of shares you wish to buy or sell and the price at which you are willing to transact. Buyers and sellers will be matched on a monthly basis with sellers who have been waiting for the longest and willing to accept a buyer’s offer being matched first. In cases where there are several sellers stating the same minimum price, sellers will be prioritised according to how long their shares have been listed."

Craven Industrial Holdings is no longer associated with Craven House Capital. Enquiries relating to CIH should be directed to info@cihplc.com. Emails regarding CIH sent to this email address will not be responded to in the future.

Hi, if a private group is set up l would be very interested to join. I am a long term holder of both Craven House entities. Thanks